X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (837) 837
Book Review (379) 379
Publication (83) 83
Book Chapter (7) 7
Conference Proceeding (3) 3
Newsletter (3) 3
Magazine Article (2) 2
Data Set (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ipilimumab (737) 737
index medicus (600) 600
melanoma (577) 577
humans (554) 554
immunotherapy (490) 490
oncology (475) 475
metastatic melanoma (340) 340
cancer (328) 328
melanoma - drug therapy (292) 292
antibodies, monoclonal - therapeutic use (265) 265
metastasis (257) 257
care and treatment (243) 243
nivolumab (233) 233
male (193) 193
survival (184) 184
female (182) 182
middle aged (178) 178
melanoma - pathology (174) 174
open-label (173) 173
chemotherapy (166) 166
antineoplastic agents - therapeutic use (162) 162
skin neoplasms - drug therapy (146) 146
pembrolizumab (143) 143
aged (140) 140
immunology (139) 139
drug therapy (136) 136
clinical trials (130) 130
treatment outcome (128) 128
antibodies, monoclonal - adverse effects (124) 124
adult (123) 123
medicine & public health (123) 123
melanoma - immunology (123) 123
research (119) 119
immunotherapy - methods (115) 115
patients (113) 113
cancer therapies (109) 109
ctla-4 (106) 106
melanoma - therapy (106) 106
safety (105) 105
vemurafenib (104) 104
tumors (102) 102
skin neoplasms - pathology (101) 101
health aspects (96) 96
therapy (96) 96
advanced melanoma (95) 95
pd-1 (92) 92
pharmacology & pharmacy (92) 92
antibodies, monoclonal - administration & dosage (91) 91
phase-ii (88) 88
double-blind (87) 87
mutation (87) 87
antigens (86) 86
ctla-4 antigen - antagonists & inhibitors (86) 86
melanoma - mortality (86) 86
ctla-4 blockade (84) 84
medical research (83) 83
analysis (79) 79
animals (79) 79
monoclonal antibodies (79) 79
prognosis (79) 79
aged, 80 and over (78) 78
t cells (78) 78
ipilimumab plus dacarbazine (77) 77
antineoplastic agents - adverse effects (76) 76
lymphocytes (76) 76
programmed cell death 1 receptor - antagonists & inhibitors (75) 75
cytotoxicity (74) 74
review (74) 74
braf (73) 73
neoplasm metastasis (73) 73
t-cells (73) 73
melanoma - secondary (72) 72
untreated melanoma (71) 71
biomarkers (70) 70
skin cancer (70) 70
malignant-melanoma (69) 69
adverse events (68) 68
antineoplastic combined chemotherapy protocols - therapeutic use (68) 68
blockade (68) 68
ctla-4 antigen - immunology (68) 68
immune checkpoint (68) 68
metastases (68) 68
immune system (67) 67
medicine, research & experimental (66) 66
cell lung-cancer (65) 65
usage (64) 64
hematology, oncology and palliative medicine (62) 62
dermatology (61) 61
clinical trials as topic (60) 60
neoplasm staging (60) 60
medical prognosis (59) 59
multicenter (56) 56
survival analysis (56) 56
antibodies (55) 55
skin neoplasms - immunology (55) 55
dabrafenib (54) 54
development and progression (54) 54
improved survival (54) 54
neoplasms - drug therapy (54) 54
cancer research (53) 53
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 26, pp. 2517 - 2526
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 11/2015, Volume 76, Issue 5, pp. 969 - 975
Ipilimumab (IPI), a monoclonal antibody against immune-checkpoint receptor cytotoxic T lymphocyte antigen-4, is designed to enhance antitumor T cell function.... 
Dacarbazine | Phase 2 study | Medicine & Public Health | Ipilimumab | Melanoma | Oncology | Cancer Research | Japanese patients | Pharmacology/Toxicology | Immune-checkpoint inhibitor | EFFICACY | COMBINATION | CANCER | TRIAL | ONCOLOGY | PHARMACOLOGY & PHARMACY | CTLA-4 | BLOCKADE | CLINICAL ACTIVITY | Dacarbazine - adverse effects | Endocrine System Diseases - chemically induced | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Neoplasm Proteins - immunology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Neoplasm Proteins - antagonists & inhibitors | Alanine Transaminase - blood | Adult | Female | Maintenance Chemotherapy | Chemical and Drug Induced Liver Injury - blood | Chemical and Drug Induced Liver Injury - etiology | Drug Eruptions - etiology | Dacarbazine - administration & dosage | Drug Administration Schedule | Japan | Kaplan-Meier Estimate | Treatment Outcome | CTLA-4 Antigen - immunology | Remission Induction | Disease Progression | Melanoma - secondary | Disease-Free Survival | Aspartate Aminotransferases - blood | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Melanoma - drug therapy | Aged | CTLA-4 Antigen - antagonists & inhibitors | Medical research | Liver | Monoclonal antibodies | Medicine, Experimental | Metastasis | T cells | Index Medicus | Original
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 1, pp. 23 - 34
Journal Article
Science, ISSN 0036-8075, 10/2015, Volume 350, Issue 6257, pp. 207 - 211
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2017, Volume 35, Issue 1, pp. 40 - 47
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 611 - 622
Journal Article